Rachel M. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rachel M. Smith has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Allison DePersia
NorthShore University HealthSystem 6
10 shared publications - Amanda Ewart Toland
Department of Cancer Biology and Genetics, Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, USA
10 shared publications - Amy Webb
Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus (A.W.).
10 shared publications - Ava Willoughby
The Ohio State University Wexner Medical Center 3 Columbus, Ohio
10 shared publications - Darcy Thull
University of Pittsburgh 10 Pittsburgh, Pennsylvania
10 shared publications - Doreen M. Agnese
The Ohio State University
10 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.
- 8 July 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis
Background: Insulin is commonly used to manage steroid-induced hyperglycemia. However, optimal dosing strategies for long-acting steroids like dexamethasone remain unclear. Objectives: This study evaluated insulin glargine use for dexamethasone-induced hyperglycemia (DIH) and evaluated factors associated with achieving glucose targets (AGTs). Methods: This retrospective, single-centered cohort study included adult, noncritically ill patients who received once-daily insulin glargine and dexamethasone for at least 3 consecutive days during admissions between July 1, 2021, and July 31, 2023. Patients were excluded if they had type 1 diabetes mellitus or received intravenous insulin within the first 3 days. The primary outcome was the percentage of patients AGT, defined as mean blood glucose 70 to 180 mg/dL on day 3 of combination therapy. Patients were then stratified into AGT and persistent hyperglycemia (PH) cohorts to evaluate secondary outcomes which included hypoglycemia incidence and patient or treatment characteristics associated with AGT. Results: Among 118 patients included, 28 (24%) were in the AGT cohort and 90 (76%) were in the PH cohort. The AGT cohort had a lower mean body mass index (29.1 vs 33.7 kg/m 2 , P = .02) and fewer patients with preexisting type 2 diabetes mellitus (85.7% vs 97.8%, P = .03). Median insulin glargine units standardized by dexamethasone dose was similar between cohorts (2.25 [1.08-3.33] vs 2.00 [1.17-4.00] units/mg/day, P = .98). The PH cohort required significantly higher median daily bolus insulin doses (24 vs 6 units/day, P < .01). There was 1 patient, who was in the AGT cohort, who experienced hypoglycemia. Conclusion and Relevance: This study suggests that current practice underdoses insulin glargine initially for DIH management and relies on reactive bolus insulin with limited success. Earlier and more assertive insulin glargine dosing is warranted to improve early glycemic control without substantially increasing hypoglycemia risk. Limitations include the retrospective single-centered study design and limited sample size with imbalanced cohorts.
- 8 July 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis
Background: Insulin is commonly used to manage steroid-induced hyperglycemia. However, optimal dosing strategies for long-acting steroids like dexamethasone remain unclear. Objectives: This study evaluated insulin glargine use for dexamethasone-induced hyperglycemia (DIH) and evaluated factors associated with achieving glucose targets (AGTs). Methods: This retrospective, single-centered cohort study included adult, noncritically ill patients who received once-daily insulin glargine and dexamethasone for at least 3 consecutive days during admissions between July 1, 2021, and July 31, 2023. Patients were excluded if they had type 1 diabetes mellitus or received intravenous insulin within the first 3 days. The primary outcome was the percentage of patients AGT, defined as mean blood glucose 70 to 180 mg/dL on day 3 of combination therapy. Patients were then stratified into AGT and persistent hyperglycemia (PH) cohorts to evaluate secondary outcomes which included hypoglycemia incidence and patient or treatment characteristics associated with AGT. Results: Among 118 patients included, 28 (24%) were in the AGT cohort and 90 (76%) were in the PH cohort. The AGT cohort had a lower mean body mass index (29.1 vs 33.7 kg/m 2 , P = .02) and fewer patients with preexisting type 2 diabetes mellitus (85.7% vs 97.8%, P = .03). Median insulin glargine units standardized by dexamethasone dose was similar between cohorts (2.25 [1.08-3.33] vs 2.00 [1.17-4.00] units/mg/day, P = .98). The PH cohort required significantly higher median daily bolus insulin doses (24 vs 6 units/day, P < .01). There was 1 patient, who was in the AGT cohort, who experienced hypoglycemia. Conclusion and Relevance: This study suggests that current practice underdoses insulin glargine initially for DIH management and relies on reactive bolus insulin with limited success. Earlier and more assertive insulin glargine dosing is warranted to improve early glycemic control without substantially increasing hypoglycemia risk. Limitations include the retrospective single-centered study design and limited sample size with imbalanced cohorts.